ProShares Ultra Health Ca... (RXL)
NYSEArca: RXL
· Цена в реальном времени · USD
63.26
+1.64 (2.66%)
На закрытии: Aug 21, 2026, 3:46 PM
ProShares Ultra Health Care (RXL): цена ETF, состав и анализ
2.66% (1D)
| Покупка | 0 |
| Рыночная капитализация | n/a |
| AUM | 84.21M |
| NAV | 63.17 |
| Бета | 0.85 |
| EPS (TTM) | н/д |
| P/E (TTM) | 33.26 |
| Акций в обращении | н/д |
| Дата запуска | Jan 30, 2007 |
| Продажа | 0 |
| Объём | 5,433 |
| Сред. объём (20Д) | 13,117 |
| Открытие | 61.70 |
| Пред. закрытие | 61.62 |
| Диапазон дня | 63.19 - 63.64 |
| Диапазон за 52 недели | 39.32 - 64.60 |
| Активы | н/д |
| Коэффициент расходов | 0.95% |
О RXL
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of health care companies included in the S&P 500 Index. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Класс активов Equity
Тикер RXL
Дата запуска Jan 30, 2007
Управляющая компания Proshares
Сайт Страница фонда
Биржа NYSEArca
Топ-10 активов 50.07% активов
| Название | Тикер | Вес |
|---|---|---|
| Eli Lilly And Co | LLY | 11.10% |
| Proshares Genius Mon... | IQMM | 10.10% |
| Johnson & Johnson | JNJ | 7.54% |
| Abbvie Inc | ABBV | 5.42% |
| Unitedhealth Group I... | UNH | 4.60% |
| Merck & Co Inc | MRK | 3.92% |
| Thermo Fisher Scient... | TMO | 2.60% |
| Amgen Inc | AMGN | 2.54% |
| Abbott Laboratories | ABT | 2.25% |
Дивиденды Дивидендная доходность 1.12%
| Дата отсечки | Сумма | Дата выплаты |
|---|---|---|
| Jun 24, 2026 | $0.1770 | н/д |
| Mar 25, 2026 | $0.1440 | н/д |
| Dec 24, 2025 | $0.1840 | н/д |
| Sep 24, 2025 | $0.2030 | н/д |
| Jun 25, 2025 | $0.2190 | н/д |
4 месяцев назад · Simply Wall St.
Rexel (ENXTPA:RXL) Valuation Check After 12% Share Price PullbackRexel (ENXTPA:RXL) has drawn attention after a recent 12% decline over the past month, with the share price closing at €32.52. This has prompted investors to reassess its fundamentals and recent perfo...